Tirzepatide – Pre-filled Pen 30mg

Tirzepatide – Pre-filled Pen 30mg

£360.00

Tirzepatide , the active substance in Mounjaro , is a dual-action peptide molecule ( GIP/GLP-1 ). Pepticore Aminos pre-filled pens are ready-to-use, single-use devices with a controlled – dispensing mechanism and a volume inspection window.

Characteristics

  • Sterile, ready-to-use pre-filled pens.
  • Visible graduated scale for volume control.
  • Ideal for metabolism studies , glycemic control and GIP/GLP-1 research .

Available variants

Select the dosage from the menu. Correspondence in 2.5 mg doses :

Variant Total content Volume 2.5 mg doses*
10 mg / 1 ml 10 mg 1.0 ml 4 doses
15 mg / 1.5 ml 15 mg 1.5 ml 6 doses
30 mg / 3 ml 30 mg 3.0 ml 12 doses
60 mg / 3 ml 60 mg 3.0 ml 24 doses

*Indicative doses calculated on 2.5 mg fractions each.

Notes

  • Product intended for research use . Not intended to diagnose, treat, or prevent disease.
Category:

What is Tirzepatide?

Tirzepatide – Pre-filled Pen 30mg is a next-generation peptide molecule developed for the treatment of type 2 diabetes and obesity . It is the active substance of the commercial drug Mounjaro , approved worldwide as a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors . This combination of hormonal targets allows for simultaneous action on blood glucose regulation, lipid metabolism, and appetite control.

Unlike previous GLP-1 agonists, Tirzepatide produces a synergistic effect that improves
glycemic control , promotes significant and sustained weight loss
, and supports improved energy efficiency.
In obese subjects, treatment with Tirzepatide demonstrated body weight reductions of up to 22.5%
over 72 weeks, as reported in the landmark
SURMOUNT-1 study (NEJM 2022) .

Mechanism of action: synergy between GIP and GLP-1

Tirzepatide – Pre-filled Pen 30mg mimics the combined action of two natural gut hormones, GIP and GLP-1, known as incretins.
These hormones are secreted after meals and contribute to the regulation of glucose and fat metabolism.
By acting on both receptors, tirzepatide amplifies the signals that control insulin secretion,
reduces glucagon levels, and modulates the appetite centers of the brain.

GIP receptor

The GIP receptor stimulates the pancreas to release insulin only when blood sugar levels are high,
minimizing the risk of hypoglycemia. It also participates in fat metabolism, influencing
the use of fatty acids as an energy source. In combination with GLP-1, this pathway promotes
the reduction of visceral fat, the type most closely associated with cardiovascular risk and insulin resistance.

GLP-1 receptor

Activation of GLP-1 reduces hunger, slows gastric emptying, and stimulates
insulin secretion in response to glucose. At the same time, it inhibits the release of glucagon,
thus lowering blood sugar levels. The combined effect improves HbA1c,
stabilizes fasting blood sugar, and facilitates the maintenance of a prolonged calorie deficit.

This dual endocrine action underpins the success of Tirzepatide,
which combines the antidiabetic properties of GLP-1 with a broader metabolic impact mediated by GIP.
Clinical results also suggest a potential role in improving vascular health
by reducing blood pressure and some systemic inflammatory markers.

Main benefits observed

  • Optimized glycemic control thanks to increased glucose-dependent insulin secretion.
  • Sustained weight loss and reduction of visceral fat mass.
  • Improved lipid profile with decreased LDL cholesterol and increased HDL.
  • Reduction of appetite and prolonged feeling of satiety after meals.
  • Positive effects on energy metabolism and cardiovascular function.

Comparison with other incretin agonists

Tirzepatide – Pre-filled Pen 30mg belongs to the same pharmacological class as semaglutide and the newer
retatrutide , but differs in the number of activated receptors and the intensity of the metabolic effect.
Comparative studies have shown that tirzepatide surpasses semaglutide in improving glycemic control
and promoting more marked weight loss, as evidenced in the
SURPASS-2 study (NEJM 2021) .

Drug Activated receptors Main effects Average weight loss (clinical data)
Semaglutide GLP-1 Satiety, slower gastric emptying, glycemic control ≈ 15% in 68 weeks
Tirzepatide GLP-1 + GIP Dual action on appetite, blood sugar and lipid metabolism ≈ 22.5% in 72 weeks ( SURMOUNT-1 )
Retatrutide GLP-1 + GIP + glucagon Increased energy expenditure and fat oxidation ≈ 24% in 48 weeks (phase 2, preliminary data)

Reviews

There are no reviews yet.

Be the first to review “Tirzepatide – Pre-filled Pen 30mg”

Your email address will not be published. Required fields are marked *

Related products

Scroll to Top